Free Trial

Embecta (EMBC) Stock Forecast & Price Target

Embecta logo
$19.82 -0.17 (-0.85%)
(As of 12/17/2024 ET)

Embecta - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Embecta in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a buy rating for EMBC.

Consensus Price Target

$23.00
16.04% Upside
According to the 2 analysts' twelve-month price targets for Embecta, the average price target is $23.00. The highest price target for EMBC is $26.00, while the lowest price target for EMBC is $20.00. The average price target represents a forecasted upside of 16.04% from the current price of $19.82.
Get the Latest News and Ratings for EMBC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Embecta and its competitors.

Sign Up

EMBC Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$23.00$12.00$12.00$16.00
Forecasted Upside16.04% Upside-16.78% Downside-23.62% Downside-10.56% Downside
Consensus Rating
Moderate Buy
Sell
Reduce
Reduce

EMBC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EMBC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Embecta Stock vs. The Competition

TypeEmbectaMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside16.04% Upside28,675.54% Upside12.02% Upside
News Sentiment Rating
Positive News

See Recent EMBC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/2/2024Morgan Stanley
3 of 5 stars
 UpgradeUnderweight ➝ Equal Weight$13.00 ➝ $20.00-3.98%
11/27/2024BTIG Research
2 of 5 stars
M. Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$26.00+39.04%
10/20/2023Wolfe Research
3 of 5 stars
 Initiated CoveragePeer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:40 AM ET.


EMBC Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Embecta is $23.00, with a high forecast of $26.00 and a low forecast of $20.00.

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EMBC shares.

According to analysts, Embecta's stock has a predicted upside of 16.04% based on their 12-month stock forecasts.

Over the previous 90 days, Embecta's stock had 2 upgrades by analysts.

Embecta has been rated by research analysts at BTIG Research, and Morgan Stanley in the past 90 days.

Analysts like Embecta less than other "medical" companies. The consensus rating score for Embecta is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how EMBC compares to other companies.


This page (NASDAQ:EMBC) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners